Many who cope with Chronic Fatigue Syndrome, Fibromyalgia, and other
chronic illnesses must also deal with sleep disturbances. Getting enough
rest is essential to good health and well-being, so many must rely on
sleep medications.
Rozerem (ramelteon)
Company: Takeda
Approval Status: Approved July, 2005
Treatment for: Insomnia
Rozerem (ramelteon) is a melatonin receptor agonist, with high binding
affinity at the melatonin MT1 and MT2 receptors, and is specifically
indicated for the treatment of insomnia characterized by difficulty in
falling asleep. Unlike many other hypnotic agents, clinical and animal
trials of Rozerem did not yield evidence of formation of physical
dependence or abuse potential, and the drug is not a controlled
substance; overall adverse events occurred at rates generally comparable
to placebo.
Chronic-Illness.org Forum Discussion on this drug
Related Articles:
Metabolic
Syndrome: The Consequences of Disrupted Sleep
by Pamela Rice Hahn |
